BILL three-lens brief
Evidence-based stock research on BILL. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Currently unprofitable on a trailing basis — no P/E multiple available.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $57.30 — 20% above current (20 analysts).
BILL closed at $47.63 (-0.65%) as of 2026-09-11. Market cap: $4.74B. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; analyst mean target $57.30 — 20% above current (20 analysts).. Concerns: currently unprofitable on a trailing basis — no P/E multiple available.. Last quarter: Revenue $436.19M, net income -$18.48M, free cash flow $222.84M.
Why three lenses on BILL, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BILLacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BILL" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BILL brief"></iframe>